Asian Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Methods for Evaluation of Ocular Insert with Classification and uses in Various Eye Diseases-A Review


Affiliations
1 Gourishankar Institute of Pharmaceutical Education and Research, Limb, Satara -41501, India
     

   Subscribe/Renew Journal


The purpose of this review is to provide an update on the current knowledge within this field of ocular drug delivery. Ocular route of drug delivery is one of the most interesting and challenging endeavors facing the pharmaceutical scientist. One of the major barriers of ocular medication is to obtain and maintain a therapeutic level at the site of action for prolonged period of time. Therefore many ophthalmic drug delivery systems are available. These are classified as conventional and non-conventional drug delivery systems. The main purpose of preparing ocular insert is to increase ocular bioavailability of drug. Ocular inserts maintain the drug concentration within a desired range. Fewer administrations are required so they increase patient compliance. In the present update, the advantages, disadvantages and requirement for success of ocular inserts, and examine the few inserts which are available on the market or are being developed by pharmaceutical companies for drug delivery. In this review, we have focused on the present area of ocuserts helps in treating eye diseases.

Keywords

Ocular Inserts, Bioavailability of Drug, Patient Compliance, Eye Diseases, Barriers of Ocular Medication.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Zaki I, Fitzgerald P, Hardy JG, Wilson CG. Comparison of effect of viscosity on the precorneal residence of solution in rabbit and man. J Pharm Pharmacol. 1986;38:463–6.

  • Rathore KS and Nema RK, (2009), Review on Ocular Inserts. IJPRIF, 1(2): 164-169.

  • Neefe CW, (1974), Contact lens for ocular drug delivery. U.S. Patent: 3,786,812.

  • Priyanka Khokhar et.al, Ocular Drug Delivery System-A Review Based on Ocuserts IJPRR 2014; 3(8), 29-41.

  • Asija Rajesh, Dadarwal Poonam, Asija Sangeeta et.al, Ocular Drug Delivery System: Ocular Insert, International Journal of Universal Pharmacy and Bio Sciences 1(2),2012,30-39

  • Zaffaroni A, Michaelsw AS and Theeuwes F, (1977), Osmotic releasing device having a plurality of release rate patterns. U.S. Patent: 4, 036, 227.

  • Bawa, R., “Ocular inserts, In: Ophathalmic drug delivery systems, Marcel Dekker, Inc., New York (Mitra. A.K edr), 1993; 58:223.

  • Attia MA, Kassem MA, Safwat S. In-vivo performance of dexomethasone ophthalmic film delivery system in the rabbit eye. International J Pharm 1988; 47: 21-30.

  • Barath S, Hiremath SR. Ocular delivery systems of pefloxacin mesylate. Pharmazie 1999; 54: 55-58.

  • Sahane NK et al, “Ocular Inserts: A Review”, Drug Invention Today, 2010,2(1):pp- 57-64.

  • Zaffaroni A et al, “Osmotic releasing device having a plurality of release rate patterns”, U.S. Patent: 1977,4, 036, 227.

  • P. Tangri et al ,“ Basics of Ocular Drug Delivery Systems ”, International Journal of Research in Pharmaceutical and Biomedical Sciences Vol. 2(4), Oct – Dec, 2011,pp.1541-1552.

  • Waugh A and Grant A: The special senses Ross and Wilson Anatomy and physiology in Health and Illness, Churchill Livingstone 197-207.

  • Chien YW: Ocular drug delivery and delivery systems, special edition, 269-296.

  • Greaves JL and Wilson CG: Treatment of diseases of the eye with mucoadhesive delivery systems. Advance Drug Delivery Review 1993; 11: 349– 383.

  • Robinson JC: Ocular anatomy and physiology relevant to ocular drug delivery, Ophthalmic Drug Delivery Systems, New York, A.K. Mitra Edition, 1993, 29–57.

  • Ozawa H, Hosaka S, Kunitomo T, Tanzawa H. Ocular inserts for controlled release of antibiotics. Biomaterials. 1984; 4 (3): 170-174.

  • Vyas SP, Khar KR. Targeted and controlled drug delivery system. 1st ed. Delhi: CBS publishers and distributors; 2002.

  • Ahmed I, Gokhale RD, Shah MV, Patton TF. Physicochemical determinants of drug diffusion across the conjunctiva, sclera and cornea. J Pharm Sci. 1987; 76: 583–6.

  • Eller MG, Schoenwald RD, Dixson JA, Segarra T, Barfknecht CF. Optimization models for corneal penetration of ethoxyzolamide analogues. J Pharm Sci. 1985;74: 155–60.

  • Huang HS, Schoenwald RD, Lac JL. Corneal penetration behavior of b blocking agents II. J Pharm Sci. 1983;72: 1272–9.

  • Y. Sultana., Acta Pharm., 2005, 55, 305.

  • G.R. Chatwal and S. Anand., “Instrumental methods of chemical analysis” Mumbai, Himalaya Publishing House, 2002,111.

  • M.D. Dhanaraju, V.R. Sivakumar, K. Bhaskar., Indian Drugs., 2002, 39, 222.

  • Ubaidulla,Udhumansha.,Reddy,Molugu.V.S.,Ruckmani,Kumaresan.,Ahmad,Farhan .J., Khar,Roop.K., 2007. Transdermal Therapeutic System of Carvedilol: Effect of Hydrophilic and Hydrophobic Matrix on In Vitro and in Vivo Characteristics.AAPS Pharmscitech.8, E1-E5.

  • Dandagi PM, Manvi FV, Patil MB, Mastiholimath VS, Rathod R. Development and evaluation of ocular films of cromolyn sodium. Indian J Pharm Sci. 2004; 66: 309-312.

  • S.N. Murthy., Biodegradable polymers matrix based ocuserts of diclofenac sodium. Indian Drugs 1997, 34, 336.

  • J. Balasubramaniam., A. Srinatha, J. K. Pandit., and Gopalnath, Indian J. of Pharm. Sci., 68(5); 2006, 626-630

  • Podder, A., B.P. Mukhopadhyay, J.K. Dattagupta and N.N. Saha, 1983. 2-(1-Naphthylmethyl)-2-Imidazoline Hydrochloride (Naphazoline hydrochloride), C H N .Cl , ana-Adrenergic Agonist. ActaCryst, 39: 495

  • J. Balasubramaniam., A. Srinatha, J. K. Pandit., and Gopalnath, Indian J. of Pharm. Sci., 68(5); 2006, 626-630.

  • U. Ubaidulla, M.V. Reddy, K. Ruckmani., AAPS PharmSciTech., 2007; 8:E1-E8.

  • Verma, S., M. Rishabha and K.S. Pramod, 2014.Extraction Characterization and Evaluation of Film Forming Capacity of Natural Polymer. Drug Delivery Letters, 4: 244-253.

  • A.S. Mundada,B. K. Shrikhande., Drug. Dev. Ind. Pharm. 2006, 32,443.

  • Banker GS, et al. Water vapour transmission properties of free polymer films. IBID 1996; 18: 458.

  • Indian Pharmacopoeia, Ministry of Health and Family Welfare, Govt. of India, New Delhi. 3rd edition, 1996: A- 117 - A- 124.

  • Vijayendra Swamy.S.M, Nanjawade B.K, 2006. Development of Sustained Ocular Drug Delivery System For Betaxolol, 40(3), 165-168.

  • Sankar V, Chandrasekaran AK, Durga S, Geetha G. Design and Evaluation of Diclofenac Sodium Ophthalmic Inserts. The Indian Pharmacist Nov- 2005; 98-100.

  • S. Ramkanth, “Design and valuation of Diclofenac sodium ocusert” 1(4), Oct.-Dec.,2009,1219.

  • S. Gupta ., Int. J of Pharmacy and Pharmaceutical Sciences., 2011, 3(2), 55.

  • Dandagi PM, et al. Development and evaluation of ocular films of cromolyn sodium. Indian J Pharm Sci. 2004; 66(3): 309-312

  • Tanwar YS et al,“ In vitro and in vivo evaluation of ocular inserts of Ofloxacin”, DARU , 2007, 15(3), pp-139-145.

  • Sreenivas SA et al,“ Ofloxacin ocular inserts: Design, Formulation and Evaluation”, IJPT, 2006, 5, pp-159-162.


Abstract Views: 183

PDF Views: 0




  • Methods for Evaluation of Ocular Insert with Classification and uses in Various Eye Diseases-A Review

Abstract Views: 183  |  PDF Views: 0

Authors

Gharge Varsha Gajanan
Gourishankar Institute of Pharmaceutical Education and Research, Limb, Satara -41501, India
Pawar Pravin
Gourishankar Institute of Pharmaceutical Education and Research, Limb, Satara -41501, India
Yadav Adhikrao
Gourishankar Institute of Pharmaceutical Education and Research, Limb, Satara -41501, India

Abstract


The purpose of this review is to provide an update on the current knowledge within this field of ocular drug delivery. Ocular route of drug delivery is one of the most interesting and challenging endeavors facing the pharmaceutical scientist. One of the major barriers of ocular medication is to obtain and maintain a therapeutic level at the site of action for prolonged period of time. Therefore many ophthalmic drug delivery systems are available. These are classified as conventional and non-conventional drug delivery systems. The main purpose of preparing ocular insert is to increase ocular bioavailability of drug. Ocular inserts maintain the drug concentration within a desired range. Fewer administrations are required so they increase patient compliance. In the present update, the advantages, disadvantages and requirement for success of ocular inserts, and examine the few inserts which are available on the market or are being developed by pharmaceutical companies for drug delivery. In this review, we have focused on the present area of ocuserts helps in treating eye diseases.

Keywords


Ocular Inserts, Bioavailability of Drug, Patient Compliance, Eye Diseases, Barriers of Ocular Medication.

References